
Vaxcyte Vaccine Protects Against 31 Pneumonia Strains
A new pneumococcal vaccine from California biotech company Vaxcyte just aced its Phase III trial, protecting against more bacterial strains than leading competitors. The breakthrough could give millions of older adults stronger defense against pneumonia and other serious infections.











